Navigation Links
RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer

LA JOLLA, Calif. and SHANGHAI, May 16, 2013 /PRNewswire/ -- RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-IL-6 monoclonal antibody with a unique pharmacologic profile that has the potential to define a new paradigm in the treatment of autoimmune diseases and cancer.

"RYI-008, with its unprecedented femtamolar potency and amazing long half-life has a therapeutic profile of once monthly, low milligram, subcutaneous dosing," said Paul Grayson , president and CEO of RuiYi. "RYI-008 is a tremendous candidate for this novel development strategy, with approximately 4.1 million biologic treatment naive rheumatoid arthritis patients in China in need of a cost effective therapeutic option.  The team at Genor has deep global development experience and strong commercial, regulatory, and government relationships in China, making them the ideal development partner. We look forward to working with them to deliver novel, breakthrough therapeutics for the Chinese healthcare system."

Joe Zhou , CEO of Genor BioPharma, commented, "The clinical data on IL-6 modulation continues to be extremely favorable in multiple diseases.  The selection by RuiYi and Genor of RYI-008 for development shows a unique understanding of a changing healthcare environment in China where the cost-effective delivery of novel efficacious medicines is of significant importance."

About RYI-008

RYI-008, also known as ARGX-109, is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. The antibody was discovered by arGEN-X, Ghent Belgium, utilizing the arGEN-X SIMPLE AntibodyTM technology, and exclusively license to RuiYi to develop and commercialize globally. 

About RuiYi

RuiYi is focused on the discovery and development of novel biologic therapeutics that meet medical and commercial needs for China's patients and healthcare system and that have the potential to be disruptive globally. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company's technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. RuiYi's executive management team has offices in La Jolla, California, and RuiYi's discovery efforts and research facility are located in the Zhangjiang Hi-Tech Park in Pudong, Shanghai, China.  For more, visit

About Genor BioPharma

Founded in 2007, Genor Biopharma Co. Ltd. is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibodies (mAbs) and Fc-fusion proteins. With a total investment of approximately $30 million, Genor has more than 10 products in the pipeline, three of which are at IND and clinical stages.  Genor has a team of approximately 110 employees, with key management members who have integrated expertise and experience in mAb drug research and development from leading Western biotech and pharmaceutical companies. Genor has established a 6,000 m2 R&D center, which includes R&D and process development labs, analytical and quality center, and a cGMP clinical production facility and is planning a commercial-scale cGMP production facility. For more, visit

SOURCE RuiYi Inc.; Genor BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CMC Biologics und RuiYi Enter treffen Vereinbarung zur Entwicklung eines neuartigen monoklonalen Anti-IL-6-Antikörpers
2. CMC Biologics et RuiYi passent un accord pour le développement dun nouvel anticorps monoclonal Anti-IL-6
3. CMC Biologics and RuiYi Enter into an Agreement for Development of a Novel Anti-IL-6 Monoclonal Antibody
4. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
5. Callidus Biopharma Announces $4.6 million in Series A Financing to Pursue Orphan Disease Therapies
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results
7. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
8. PDL BioPharma to Announce First Quarter 2013 Financial Results on May 9, 2013
9. Rutgers Business School and the Blanche and Irwin Lerner Center will explore trends and issues facing the biopharmaceutical industry at a healthcare symposium, Tuesday, April 30
10. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
11. New PAREXEL Report Defines The Next Generation Of Strategic Partnerships Between CROs And Biopharmaceutical Industry
Post Your Comments:
(Date:11/26/2015)... , 26 november 2015 AAIPharma ... de geplande investering aan van ten minste ... laboratoria en het mondiale hoofdkantoor in ... zal resulteren in extra kantoorruimte en extra ... de groeiende behoeften van de farmaceutische en ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... 2015 Research and Markets ( ) has ... Market Outlook to 2019 - Rise in Cardiac Disorders and ... report to their offering. Boston ... scientific and others. --> The ... Boston scientific and others. ...
Breaking Medicine Technology:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST ... the most savings. , With possible savings of up to 20% off orders $80 or ... homepage of the website every few hours. , As a competitive e-commerce website for skin ...
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... , ... November 27, 2015 , ... According to an ... by the University of Toronto and the University of British Columbia suggested that laws ... head injuries. The article explains that part of the reason for the controversial conclusion ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the health care in America. As people age, more care is needed, especially ... are rising, and medical professionals are being overworked. The forgotten part of this ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, from ... dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. , ... prescription medications. In doing so, it could help to prevent potential overdose situations. ...
Breaking Medicine News(10 mins):